Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Motixafortide Acetate bulk supplier for pharma manufacturers

Motixafortide Acetate 1 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 1 mg/mL

Reference Brands: Aphexda (USA)

Category: Oncology Cancer Care

Motixafortide Acetate is a Oncology Cancer Care product available as Injection in strengths 1 mg/mL. It corresponds to the reference brand Aphexda (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide

Product Description:

Motixafortide, marketed under the brand name Aphexda, is a synthetic cyclic peptide that functions as a selective CXCR4 antagonist and hematopoietic stem cell mobilizer. It is primarily used in patients with multiple myeloma to facilitate the collection of hematopoietic stem and progenitor cells for autologous transplantation. Administered via subcutaneous injection, Motixafortide works by blocking the CXCR4 receptor, disrupting the retention of stem cells in the bone marrow, and promoting their release into the peripheral blood.

The drug is indicated for use in combination with filgrastim, a granulocyte-colony stimulating factor (G-CSF), which enhances stem cell mobilization and improves collection efficiency. This combination provides a predictable and effective method for harvesting sufficient stem cells for transplantation. Motixafortide’s rapid onset and targeted mechanism make it a valuable option in clinical settings, offering a controlled and efficient approach to stem cell mobilization for patients undergoing autologous transplant procedures.

Motixafortide Acetate — third party manufacturing & bulk supply

Motixafortide Acetate 1 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

What to include when you enquire

  • Destination market — determines which manufacturers hold the right site-level approvals
  • First order quantity and estimated annual volume
  • Whether you need a registration dossier or the product is already registered
  • Packaging, labelling and language requirements
  • Incoterms and required shelf life

Manufacturers of Motixafortide Acetate listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.

Request a quote for Motixafortide Acetate →
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions


Motixafortide Acetate is used to mobilize hematopoietic stem and progenitor cells from the bone marrow into the peripheral blood. It is primarily administered in combination with granulocyte-colony stimulating factor (G‑CSF) to enhance stem cell collection for autologous transplantation in patients with multiple myeloma.


Motixafortide Acetate is a synthetic cyclic peptide designed as a selective antagonist of the C‑X‑C Motif Chemokine Receptor 4 (CXCR4). It is formulated as the acetate salt for stability and subcutaneous administration.


Motixafortide Acetate is marketed under the brand name Aphexda.


Motixafortide Acetate is manufactured by The Medicines Company and other authorized pharmaceutical manufacturers producing hospital injectable formulations.


The generic name of the product is motixafortide acetate.


The brand name is Aphexda.


Motixafortide Acetate is manufactured in GMP-compliant facilities, including locations in the USA and Europe, for clinical and hospital use.

Related Products

Fruquin 5 Mg (Fruquintinib)

Strength:
5 Mg

Form: Capsules

Reference Brands: Everest Bangladesh altd.

View Details
Vorinostat

Strength:
100 mg

Form: Capsules

Reference Brands: Zolinza (USA/EU), Vornat (India)

View Details
Panobinostat Lactate

Strength:
10 mg, 15 mg, 20 mg

Form: Capsules

Reference Brands: Farydak (USA/EU),

View Details
Gilteritinib

Strength:
40 mg

Form: Tablets

Reference Brands: Xospata (USA/India), LuciGil (Asia)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.